Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome
(2012) In Clinical Biochemistry 45(7-8). p.535-540- Abstract
- Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard... (More)
- Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% CI 1.28-3.78, p = 0.0046) and 1.75 (1.22-2.51, p = 0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p = 0.0016) and 1.76 (1.23-2.53, p = 0.0022), respectively. Creatinine was not an independent predictor of endpoints (p > 0.05). Conclusions: Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2551645
- author
- Ristiniemi, Noora ; Lund, Juha ; Tertti, Risto ; Christensson, Anders LU ; Ilva, Tuomo ; Porela, Pekka ; Pulkki, Kari and Pettersson, Kim
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Acute coronary syndrome, Cystatin C, Kidney, Myocardial infarction, Renal insufficiency, Risk
- in
- Clinical Biochemistry
- volume
- 45
- issue
- 7-8
- pages
- 535 - 540
- publisher
- Elsevier
- external identifiers
-
- wos:000303553300005
- scopus:84860210769
- ISSN
- 1873-2933
- DOI
- 10.1016/j.clinbiochem.2012.02.012
- language
- English
- LU publication?
- yes
- id
- e0f62c23-421b-4037-9cb2-e13e7d15ae27 (old id 2551645)
- date added to LUP
- 2016-04-01 10:43:05
- date last changed
- 2022-04-20 05:29:43
@article{e0f62c23-421b-4037-9cb2-e13e7d15ae27, abstract = {{Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% CI 1.28-3.78, p = 0.0046) and 1.75 (1.22-2.51, p = 0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p = 0.0016) and 1.76 (1.23-2.53, p = 0.0022), respectively. Creatinine was not an independent predictor of endpoints (p > 0.05). Conclusions: Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.}}, author = {{Ristiniemi, Noora and Lund, Juha and Tertti, Risto and Christensson, Anders and Ilva, Tuomo and Porela, Pekka and Pulkki, Kari and Pettersson, Kim}}, issn = {{1873-2933}}, keywords = {{Acute coronary syndrome; Cystatin C; Kidney; Myocardial infarction; Renal insufficiency; Risk}}, language = {{eng}}, number = {{7-8}}, pages = {{535--540}}, publisher = {{Elsevier}}, series = {{Clinical Biochemistry}}, title = {{Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome}}, url = {{http://dx.doi.org/10.1016/j.clinbiochem.2012.02.012}}, doi = {{10.1016/j.clinbiochem.2012.02.012}}, volume = {{45}}, year = {{2012}}, }